Ardelyx

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Ardelyx and other ETFs, options, and stocks.

About ARDX

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. 

CEO
Michael G. Raab
CEOMichael G. Raab
Employees
395
Employees395
Headquarters
Waltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded
2007
Founded2007
Employees
395
Employees395

ARDX Key Statistics

Market cap
1.45B
Market cap1.45B
Price-Earnings ratio
-24.48
Price-Earnings ratio-24.48
Dividend yield
Dividend yield
Average volume
3.07M
Average volume3.07M
High today
$5.83
High today$5.83
Low today
$5.72
Low today$5.72
Open price
$5.83
Open price$5.83
Volume
1.97M
Volume1.97M
52 Week high
$6.78
52 Week high$6.78
52 Week low
$3.21
52 Week low$3.21

Stock Snapshot

With a market cap of 1.45B, Ardelyx(ARDX) trades at $5.80. The stock has a price-to-earnings ratio of -24.48.

On 2025-12-24, Ardelyx(ARDX) stock moved within a range of $5.72 to $5.83. With shares now at $5.80, the stock is trading +1.4% above its intraday low and -0.5% below the session's peak.

Trading activity shows a volume of 1.97M, compared to an average daily volume of 3.07M.

Over the past 52 weeks, Ardelyx(ARDX) stock has traded between a high of $6.78 and a low of $3.21.

Over the past 52 weeks, Ardelyx(ARDX) stock has traded between a high of $6.78 and a low of $3.21.

ARDX News

Simply Wall St 19h
Do Ardelyx’s Leadership Changes Reframe How Investors View Its Long-Term Pipeline Strategy?

Ardelyx, Inc. has announced that Chief Legal and Administrative Officer Elizabeth Grammer and Chief Medical Officer Edward Conner resigned effective December 31...

Do Ardelyx’s Leadership Changes Reframe How Investors View Its Long-Term Pipeline Strategy?
Simply Wall St 2d
Ardelyx: Revisiting Valuation After a Strong Multi‑Year Shareholder Return Run

Ardelyx (ARDX) has quietly outperformed many small-cap biotechs this year, and its mix of rising revenue and shrinking losses is drawing fresh attention from in...

Ardelyx: Revisiting Valuation After a Strong Multi‑Year Shareholder Return Run
TipRanks 6d
Ardelyx Announces Key Leadership Transitions

Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper...

Analyst ratings

91%

of 11 ratings
Buy
90.9%
Hold
9.1%
Sell
0%

People also own

Based on the portfolios of people who own ARDX. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.